Pemetrexed/cisplatin (pem/cis) Vs. Pemetrexed/carboplatin (pem/carbo) In Non-squamous, Non-small Cell Lung Cancer (nsclc): A Retrospective Comparison Using A Large Electronic Database

被引：0
|
作者：
Hoverman, J. R. [1 ]
Sheth, S. [1 ]
Clayton, M. [1 ]
Neubauer, M. [1 ]
Brooks, B. [1 ]
Garey, J. [1 ]
Beveridge, R. [1 ]
机构：
[1] McKesson Specialty Hlth, US Oncol Network, The Woodlands, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S273 / S273
页数：1
相关论文
共 50 条
  • [1] Comparative effectiveness of carboplatin-pemetrexed (Carbo-Pem) with vs. without bevacizumab (Bev) in patients with advanced non-squamous (Sq) non-small cell lung cancer (NSCLC).
    Bagley, Stephen Joseph
    Mitra, Nandita
    Meropol, Neal J.
    Holzman, Benjamin
    Cohen, Roger B.
    Langer, Corey J.
    Vachani, Anil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] COST EFFECTIVENESS OF PEMETREXED/CISPLATIN (PEM/CIS) IN THE TREATMENT OF ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSQNSCLC) PATIENTS
    Winfree, K. B.
    Shah, M.
    Peterson, P.
    Gruschkus, S.
    Eaddy, M.
    Green, M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 428 - 428
  • [3] PHARMACOKINETIC (PK) ANALYSIS OF COADMINISTRATION OF AXITINIB AND PEMETREXED/CISPLATIN (PEM/CIS) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC).
    Tortorici, M. A.
    Iglesias, L.
    Kozloff, M. F.
    Pithavala, Y. K.
    Ingrosso, A.
    Belani, C. P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S33 - S33
  • [4] The role of cisplatin (CDDP) or carboplatin (CARBO) plus pemetrexed (PEM) in nonsquamous (NON-SQM) non-small cell lung cancer (NSCLC): Results of an Italian retrospective multicentric study.
    Parra, Hector J. Soto
    Favaretto, Adolfo G.
    Bearz, Alessandra
    Cortinovis, Diego Luigi
    Galetta, Domenico
    Cinierl, Saverlo
    Adamo, Vincenzo
    Giannitto-Giorgio, Carmelo
    Tralongo, Paolo
    Barllino, Nicola
    Spada, Massimiliano
    Ferrau, Francesco
    Butera, Alfredo
    Barbieri, Vito
    Blasi, Livio
    Aiello, Marco M.
    Restuccia, Nunzio
    Franchina, Tindara
    Alu, Massimillano
    Bruzzi, Paolo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] IMpower132: Efficacy of atezolizumab (atezo) plus carboplatin (carbo)/cisplatin (cis) plus pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)
    Barlesi, F.
    Nishio, M.
    Cobo, M.
    Steele, N.
    Paramonov, V.
    Parente, B.
    Dear, R.
    Berard, H.
    Peled, N.
    Seneviratne, L. C.
    Baldini, E.
    Watanabe, S.
    Goto, K.
    Mendus, D.
    Patel, H.
    Deng, Y.
    Kowanetz, M.
    Hoang, T.
    Lin, W.
    Papadimitrakopoulou, V. A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 743 - +
  • [6] CARBOPLATIN AND PEMETREXED FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER - OVERALL SURVIVAL AND TOXICITY
    Andersen, R.
    Mellemgaard, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S73 - S73
  • [7] Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results
    Patel, J. D.
    Hensing, T. A.
    Villafor, V.
    Hart, E.
    Bonomi, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer
    Afzal, Muhammad Zubair
    Dragnev, Konstantin
    Shirai, Keisuke
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (06) : 3575 - 3584
  • [9] A retrospective study of maintenance pemetrexed in advanced non-squamous non-small cell lung cancer
    Oguh, L.
    Ranatunge, D.
    Lind, M.
    Ukadhyay, S.
    El-Mahdawi, N.
    [J]. LUNG CANCER, 2018, 115 : S30 - S30
  • [10] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345